Investing.com - DiaMedica Therapeutics (NASDAQ: DMAC) reported third quarter EPS of $-0.120, $0.01 better than the analyst estimate of $-0.130. Revenue for the quarter came in at $0.00 versus the consensus estimate of $0.
DiaMedica Therapeutics's stock price closed at $2.340. It is down -17.610% in the last 3 months and up 98.310% in the last 12 months.
DiaMedica Therapeutics saw 3 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See DiaMedica Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, DiaMedica Therapeutics's Financial Health score is "good performance".
Check out DiaMedica Therapeutics's recent earnings performance, and DiaMedica Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar